"The OASIS 4 phase 3 trial, published in The New England Journal of Medicine, marks a major advance in Novo Nordisk's effort to expand obesity treatment options. Conducted over 64 weeks, the study compared once-daily oral semaglutide 25 mg plus lifestyle changes with a placebo in 307 adults who were obese or overweight and had at least one weight-related condition, but did not have diabetes."
"Participants who consistently adhered to treatment achieved an average weight loss of 16.6% versus 2.7% for those taking placebo. Over one-third (34.4%) lost at least 20% of their body weight compared with 2.9% in the placebo group. These outcomes were similar to previous results with injectable Wegovy. When measured regardless of treatment adherence, average weight loss was 13.6% for the semaglutide group compared with 2.2% for placebo."
"In addition to significant weight reduction, those taking oral semaglutide 25 mg experienced improvements in daily physical function, including activities such as bending, walking, standing, and overall mobility, along with better cardiovascular risk profiles. Novo Nordisk has submitted the treatment to the US Food and Drug Administration (FDA) as the first oral GLP-1 therapy for long-term weight management.2 Production of the medication is already underway at the company's facilities in the United States."
Oral semaglutide 25 mg produced substantial weight losses in adults with obesity, with adherent participants averaging 16.6% weight reduction and 34.4% losing at least 20% of body weight. The 64-week OASIS 4 phase 3 trial randomized 307 adults without diabetes to once-daily oral semaglutide plus lifestyle changes or placebo. When analyzed regardless of adherence, the semaglutide group lost 13.6% on average versus 2.2% for placebo. Participants also recorded improved daily physical function and better cardiovascular risk profiles. Novo Nordisk has submitted the oral formulation for FDA approval and has begun U.S. production.
Read at ScienceDaily
Unable to calculate read time
Collection
[
|
...
]